Progress towards early development value inflection points is critical to a life science company’s ability to re-finance or secure sought after R&D deals and licensing with Pharma. One Nucleus seeks to bring timely and accurate information to our network that enables them to make informed decisions and be well connected to implement their plans. Our members think internationally and thus so do we.  Many companies look towards Australia as a location for early studies for a variety of reasons. 

In brief, Australia is one of the top three destinations for outsourced early phase clinical trials (along with US and China). Australia offers the Speed, Cost and Quality advantages. An IND is not required to open an early phase clinical study in Australia and offers an attractive R&D tax incentive (43.5%) to eligible companies. Australia is part of OECD so the data is recognised by EMEA and FDA. It is reported that conducting a study in AUS vs US (IND required) or EU can save a biotech 6-12 months off their clinical timeline. 

This afternoon tea, hosted with 360biolabs, Australia’s most comprehensive bioanalytical lab, offering a diverse range of PK and PD endpoints for clinical trials, will introduce attendees to the Australian ecosystem, regulatory requirements, R&D tax and PK/PD options for clinical trial endpoints.

Prices:
Members: Free
Non-members: £50 +VAT
Academics: please contact info@onenucleus.com

If you have any questions about this event, please contact Tony Jones on tony@onenucleus.com.